Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been given a consensus rating of “Moderate Buy” by the five research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.00.

A number of research firms recently weighed in on VTYX. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Wells Fargo & Company lowered their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Canaccord Genuity Group lowered their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Finally, HC Wainwright reissued a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th.

Ventyx Biosciences Stock Up 23.3 %

VTYX stock opened at $2.54 on Friday. Ventyx Biosciences has a fifty-two week low of $1.67 and a fifty-two week high of $11.48. The firm’s 50-day simple moving average is $2.19 and its 200 day simple moving average is $2.61. The stock has a market cap of $179.60 million, a PE ratio of -1.08 and a beta of 0.37.

Insider Activity

In other Ventyx Biosciences news, CEO Raju Mohan acquired 261,752 shares of Ventyx Biosciences stock in a transaction dated Monday, November 25th. The stock was bought at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the transaction, the chief executive officer now owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 18.18% of the company’s stock.

Hedge Funds Weigh In On Ventyx Biosciences

Several large investors have recently made changes to their positions in VTYX. Palumbo Wealth Management LLC bought a new position in shares of Ventyx Biosciences during the 3rd quarter valued at about $26,000. China Universal Asset Management Co. Ltd. increased its position in shares of Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after acquiring an additional 5,310 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Ventyx Biosciences in the second quarter worth approximately $32,000. Intech Investment Management LLC purchased a new position in shares of Ventyx Biosciences in the third quarter worth approximately $42,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after acquiring an additional 7,096 shares in the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.